by British Medical Journal Credit: CC0 Public DomainMany cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited (“fast track”) pathways, finds a study published by The BMJ. Despite pharmaceutical industry claims that high drug prices are needed to offset research and development...
Tag: <span>added benefit</span>
Post
Remdesivir in COVID-19: Indication of considerable added benefit for a part of the patients
INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE Since July 2020, remdesivir has been conditionally approved in Europe for the treatment of coronavirus disease (COVID-19) in adults and adolescents aged 12 years and older with pneumonia who require supplemental oxygen but no invasive ventilation. In an early benefit assessment, the German Institute for Quality and...